Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Clinical trial NCT07087860 · RECRUITING

Trial details

NCT number: NCT07087860
Sponsor: Mayo Clinic
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Bladder Urothelial Carcinoma Metastatic Renal Pelvis and Ureter Urothelial Carcinoma Refractory Bladder Urothelial Carcinoma Refractory Renal Pelvis and Ureter Urothelial Carcinoma Stage IV Bladder Cancer AJCC v7 Stage IV Renal Pelvis and Ureter Cancer AJCC v7

Start date: 2025-08-01
Primary completion: 2028-08-07
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.